Cargando…

Identification of Glypican-3 as a potential metastasis suppressor gene in gastric cancer

Gastric cancer is a prevalent tumor that is usually detected at an advanced metastatic stage. Currently, standard therapies are mostly ineffective. Here, we report that Glypican-3 (GPC3) is absent in invasive tumors and metastatic lymph nodes, in particular in aggressive and highly disseminated sign...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Shiwei, Ma, Xuemei, Zhao, Yanxia, Zhao, Hongying, Batista, Ana, Zhou, Sheng, Zhou, Xiaona, Yang, Yao, Wang, Tingting, Bi, Jingtao, Xia, Zheng, Bai, Zhigang, Garkavtsev, Igor, Zhang, Zhongtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190106/
https://www.ncbi.nlm.nih.gov/pubmed/27259271
http://dx.doi.org/10.18632/oncotarget.9763
Descripción
Sumario:Gastric cancer is a prevalent tumor that is usually detected at an advanced metastatic stage. Currently, standard therapies are mostly ineffective. Here, we report that Glypican-3 (GPC3) is absent in invasive tumors and metastatic lymph nodes, in particular in aggressive and highly disseminated signet ring cell carcinomas. We demonstrate that loss of GPC3 correlates with poor overall survival in patients. Moreover, we show that absence of GPC3 causes up-regulation of MAPK/FoxM1 signaling and that blockade of this pathway alters cellular invasion. An inverse correlation between GPC3 and FoxM1 is also shown in patient samples. These data identify GPC3 as a potential metastasis suppressor gene and suggest its value as a prognostic marker in gastric cancer. Development of therapies targeting signaling downstream of GPC3 are warranted.